Article: Urokinase-type plasminogen activator and insulin-like growth factor-binding protein 3 mRNA expression in endometriotic lesions and eutopic endometrium: implications for the pathophysiology of endometriosis.
Annals of the New York Academy of Sciences
2003 Volume 997, Page(s) 223–228
Abstract: The peritoneal fluid of women with endometriosis contains an increased insulin-like growth factor 1 (IGF-1) bioavailability, which is produced by limited hydrolysis of urokinase-type plasminogen activator (uPA) on IGF-binding protein 3 (IGFBP-3). ... ...
| Abstract | The peritoneal fluid of women with endometriosis contains an increased insulin-like growth factor 1 (IGF-1) bioavailability, which is produced by limited hydrolysis of urokinase-type plasminogen activator (uPA) on IGF-binding protein 3 (IGFBP-3). Recently, IGF-1 was shown to inhibit apoptosis of endometrial-like cells in vitro, suggesting that a microenvironment of increased IGF-1 bioavailability can optimize the survival of endometrial cells grown ectopically. Here the expression of mRNA of IGFBP-3 and uPA in tissue biopsies from eutopic endometrium and endometriotic lesions obtained at laparoscopy from women with endometriosis have been analyzed, and it is documented that both IGFBP-3 and uPA mRNA expression are increased from 3- to 10-fold in endometriotic lesions versus eutopic endometrium. Consequently, the necessary components (uPA and IGFBP-3 expression) of endocrine/autocrine/paracrine enhancement of local IGF bioavailability mediated by uPA hydrolysis of the IGFBP-3 were present in endometriotic lesions. These data possibly explain the origin of the increased content of uPA activity, IGF-1 bioavailability, and NH(2)-truncated forms of IGFBP-3 in the peritoneal fluid of women with endometriosis. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Ascitic Fluid ; Biopsy, Needle ; Case-Control Studies ; Culture Techniques ; Endometriosis/genetics ; Endometriosis/pathology ; Female ; Gene Expression Regulation ; Genetic Markers ; Genetic Predisposition to Disease ; Humans ; Insulin-Like Growth Factor Binding Protein 3/analysis ; Insulin-Like Growth Factor Binding Protein 3/genetics ; Probability ; RNA, Messenger/analysis ; Reference Values ; Reverse Transcriptase Polymerase Chain Reaction/methods ; Risk Assessment ; Sensitivity and Specificity ; Urokinase-Type Plasminogen Activator/analysis ; Urokinase-Type Plasminogen Activator/genetics | |||||
| Chemical Substances | Genetic Markers ; Insulin-Like Growth Factor Binding Protein 3 ; RNA, Messenger ; Urokinase-Type Plasminogen Activator (EC 3.4.21.73) | |||||
| Language | English | |||||
| Publishing date | 2003-11 | |||||
| Publishing country | United States | |||||
| Document type | Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't | |||||
| ZDB-ID | 211003-9 | |||||
| ISSN | 1749-6632 ; 0077-8923 | |||||
| ISSN (online) | 1749-6632 | |||||
| ISSN | 0077-8923 | |||||
| DOI | 10.1196/annals.1290.025 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Se 110: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.